Soleno Therapeutics (SLNO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	87.93 mm	87.93 mm	87.93 mm	87.93 mm	87.93 mm	87.93 mm
Cash burn (monthly)	(no burn)	6.81 mm	19.71 mm	15.64 mm	8.00 mm	5.76 mm
Cash used (since last report)	n/a	14.12 mm	40.84 mm	32.41 mm	16.57 mm	11.93 mm
Cash remaining	n/a	73.81 mm	47.09 mm	55.51 mm	71.35 mm	75.99 mm
Runway (months of cash)	n/a	10.8	2.4	3.5	8.9	13.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

SLNO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	176	147	+19.7%
Opened positions	51	45	+13.3%
Closed positions	22	15	+46.7%
Increased positions	78	56	+39.3%
Reduced positions	25	29	-13.8%

13F shares	Current	Prev Q	Change
Total value	2.21 tn	2.31 tn	-4.1%
Total shares	76.80 mm	72.87 mm	+5.4%
Total puts	2.62 mm	472.30 k	+453.8%
Total calls	2.53 mm	878.30 k	+188.3%
Total put/call ratio	1.0	0.5	+92.1%

Largest owners	Shares	Value	Change
Jack W. Schuler Living Trust	11.91 mm	$35.02 mm	0.0%
Vivo Capital	6.29 mm	$282.82 bn	0.0%
Vivo Opportunity Fund	6.29 mm	$313.71 mm	0.0%
JHG Janus Henderson	5.19 mm	$233.13 bn	+27.1%
Nantahala Capital Management	3.93 mm	$176.61 bn	+20.1%
Larry N Feinberg	3.73 mm	$7.20 mm	0.0%
Adage Capital Management	3.32 mm	$185.11 mm	0.0%
Adage Capital Partners GP, L.L.C.	2.78 mm	$124.78 bn	-16.4%
Avoro Capital Advisors	2.53 mm	$113.50 bn	+15.8%
BlackRock	2.01 mm	$90.34 bn	-0.1%

Largest transactions	Shares	Bought/sold	Change
CG The Carlyle Group Inc.	1.38 mm	-2.70 mm	-66.2%
Perceptive Advisors	1.50 mm	-1.70 mm	-53.2%
JHG Janus Henderson	5.19 mm	+1.11 mm	+27.1%
Citadel Advisors	972.41 k	+950.67 k	+4372.9%
Nantahala Capital Management	3.93 mm	+658.52 k	+20.1%
Alyeska Investment	424.08 k	-552.02 k	-56.6%
Adage Capital Partners GP, L.L.C.	2.78 mm	-546.17 k	-16.4%
Westfield Capital Management	881.46 k	+385.75 k	+77.8%
Holocene Advisors	955.47 k	+361.10 k	+60.8%
Siren, L.L.C.	351.82 k	+351.82 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SLNO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jan 25	Anish Bhatnagar	Common Stock	Grant	Acquire A	No	No	0	53,900	0.00	752,362
21 Jan 25	Anish Bhatnagar	Employee stock option Common Stock	Grant	Acquire A	No	No	49.17	115,600	5.68 mm	115,600
21 Jan 25	Hirano Patricia C	Common Stock	Grant	Acquire A	No	No	0	6,400	0.00	112,302
21 Jan 25	Hirano Patricia C	Employee stock option Common Stock	Grant	Acquire A	No	No	49.17	13,800	678.55 k	13,800
21 Jan 25	Michael F. Huang	Common Stock	Grant	Acquire A	No	No	0	6,400	0.00	41,400
21 Jan 25	Michael F. Huang	Employee stock option Common Stock	Grant	Acquire A	No	No	49.17	13,800	678.55 k	13,800
21 Jan 25	James H Mackaness	Common Stock	Grant	Acquire A	No	No	0	14,500	0.00	125,798
21 Jan 25	James H Mackaness	Employee stock option Common Stock	Grant	Acquire A	No	No	49.17	31,000	1.52 mm	31,000
21 Jan 25	Yen Kristen	Common Stock	Grant	Acquire A	No	No	0	6,400	0.00	83,005
21 Jan 25	Yen Kristen	Employee stock option Common Stock	Grant	Acquire A	No	No	49.17	13,800	678.55 k	13,800

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Soleno Therapeutics Q4 2024 GAAP EPS $(1.27) Misses $(0.94) Estimate

27 Feb 25

Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(0.94) by 35.11 percent. This is a 284.85 percent decrease over losses of $(0.33) per share

Press releases

From Benzinga Pro

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

29 Jan 25

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

17 Dec 24

REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,